Overview

Study of Evobrutinib in Participants With RMS

Status:
Terminated

Trial end date:
2020-05-20

Target enrollment:

Participant gender:

Summary

The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).

Phase:

Phase 3

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Interferon beta-1a
Interferon-beta
Interferons